Eric Percher

CEO said the investment framework is unchanged, concentrated in faster-growing, more specialized and fragmented areas (Specialty MSOs, at-Home), and that capacity additions are tied to the long-term plan and automation, not a build-it-and-they-will-come approach.

CEO explained the shift from nonequity to equity MSO model, noting the market favored equity arrangements. Broader Specialty and oncology strategy remains unchanged with 20%+ and 30%+ growth respectively.

Aaron noted $750M baseline buyback completed, $600-650M CapEx on track, leverage back within 2.75-3.25x target range. Jason emphasized strategy not predicated on significant M&A. Smaller bolt-on MSO acquisitions possible. At-Home market remains fragmented. Will be opportunistic on additional repurchases. Cash at lower end historically but flexibility from multiple levers.

Aaron detailed at-Home up 51% (with ADS), Nuclear up 17%, OptiFreight up 21%. ADS synergies realizing faster than planned. Core at-Home strength in urology, CGM, enteral. Jason emphasized both core and acquisition are significant contributors, not just M&A driven.

Jason described urology as enterprise sweet spot spanning Specialty Networks, Nuclear (PSMA therapies), and at-Home Solutions. Solaris brings $1.5B revenue, <1/3 drug spend, diverse ancillary revenue. Aaron sized EBITDA at ~$125M, cash outlay $1.9B for 75% stake, $2.4B enterprise value.

Jason clarified majority of $200-300M remaining exposure will be addressed through pricing, primarily on Cardinal brand. National brand is largely pass-through/fee-for-service.

Jason confirmed Cardinal brand still growing. Weakness in respiratory/lab products not impacting at-Home. At-Home revenue up 13% with strong CGM and urology growth.

Jason confirmed GLP-1 inventory levels are static and low, not a meaningful driver of earnings or cash flow. GLP-1 contributed 5% of 16% revenue growth.

Bob emphasized the breadth of Cencora's customer base and said 340B changes would have varied puts and takes across the business rather than being uniformly negative. He declined to size the impact until something is actually implemented.

Bob emphasized distribution services contribute approximately $80 billion annually to healthcare system efficiency. Value proposition includes technology, automation, security, and data analytics. Not automatic, requires commercial negotiation, but decades of investment support confidence.

Jim clarified: first 4 months had 35% equity method (below OI line, small number). Last 8 months of fiscal year at operating income level. OneOncology contribution expected to ramp through the year from organic and inorganic growth.

Jim attributed Q4 international decline entirely to PharmaLex. World Courier rebounded with revenue and profit growth. Alliance performing well especially in 3PL. More tailored portfolio plus easier comps support 5-8% long-term guide.

Jim reiterated no material financial impacts. Bob added they are not changing sourcing practices, monitoring risk of generic shortages and patient access disruption. Playing education role in Washington on supply chain implications.

Bob expressed confidence in MSO income streams but did not break out drug vs medical or government vs commercial. Highlighted clinical trial services at RCA as expansion opportunity into OneOncology.

Bob highlighted physician leadership, value creation through clinical trials and analytics, and long-term pathway for new physicians. Jim confirmed RCA details start in Q2 reporting.

Bennett clarified no deviation or acceleration, the specialty strength in physician practices and health systems is a continuation of multi-year trends.

Andrew attributed growth to the weight-loss assortment pivot and men's hormonal reacceleration; Yemi confirmed Eucalyptus (~$40M) is included but the guide is driven mainly by domestic acceleration.

Andrew answered directly, framing HIMS as the distribution front door innovative pharma/biotech/device partners need to reach consumers.

Andrew said the international mix will converge toward the diversified U.S. model over time and expects brand relationships with drug makers to stay consistent.

Okupe reaffirmed the $725M-or-greater weight-loss target, citing continued strength in both oral offerings (broader eligibility, lower price) and GLP-1s.

Yemi said the step-down reflects offboarding commercial GLP-1 dosages; remaining oral and personalized sema products drive renewed growth with a Q4 rev-rec acceleration.

Andrew said personalized semaglutide stays under the 503A exemption but is limited to clinically necessary cases, framing it as additive; direct.

Andrew directly acknowledged customers on commercial dosing must be notified to seek alternatives, with the transition built into guidance, candid and direct.

Brian attributed 24% ex-FCS segment growth to organic market growth, same-store visit gains, and physician recruitment; Kenny said 15% organic is sustainable to the long-term target.

Brian provided detailed policy assessment: IRA Part D first 10 drugs live in January with constructive manufacturer conversations; MFN largely niche cash-paying population; GLOBE exempts IRA drugs, covers only 25% of ZIP codes and 35% of oncology Medicare, with rebate mechanism going direct from manufacturer to Medicare without impacting provider reimbursement.

Brian confirmed strong oncology volumes from existing footprint plus new partners, with more complicated patients treated as network matures. Britt explained market decisions involve entering or exiting markets based on strategic alignment, 2 exits this quarter plus an equity investment gain totaling $51M.

Britt emphasized consistent operating performance driven by utilization, program maturity, and new product launches, with continued investment in adjacencies supporting long-term growth.

Brian attributed growth to differentiated platforms and strategic customer wins. Britt detailed core pharma growth assumption of 6% to 9% ex-acquisitions, with acquisitions contributing 6% to 7%.

Brian confirmed stable utilization and strong oncology growth with 6% same-store visits, attributing performance to differentiated specialty assets and scale.

Britt spoke to demand-driven working capital management but gave no specific visibility metrics.

Shah definitively stated pressure is not from TrueCost but from three factors: slower GLP-1 compounding volume return, autoimmune category shifts, and HIV category product changes.

Newman confirmed all HS guidance reduction from HCD. Noted 2H earnings roughly evenly split between quarters with slight Q4 tilt. Shah reported strong 2026 selling season and high 90s retention.